Dose-intensified pirarubicin-cyclophosphamide, vincristine and prednisolone regimen (Double-THP-COP) followed by consolidative high-dose chemotherapy for peripheral T-cell lymphomas: a prospective phase II trial.
Phase 2
- Conditions
- ewly diagnosed adult peripheral T cell lymphoma patients, including those with peripheral T-cell lymphoma, not otherwise specified, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma (ALK negative), enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma.
- Registration Number
- JPRN-UMIN000012664
- Lead Sponsor
- ihon University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 4 serum total Bilirubin > 1.5mg/dl serum creatinine >2.0mg/dl Ejection-Fraction<50% by electrocardiogram If these complications described above are considered to be attributed to underlying disease, those patients are included when the complications are recovered with the standard treatment. Invasion to the central nervous system from the first diagnosis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method